{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:56:37Z","timestamp":1781636197432,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024603","name":"Blue Earth Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024603","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07786-6","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T05:23:37Z","timestamp":1771651417000},"page":"4862-4872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Value of a repeat 18F-flotufolastat PET scan following a negative scan in patients with suspected biochemical recurrence of prostate cancer after radical prostatectomy"],"prefix":"10.1007","volume":"53","author":[{"given":"Sonja","family":"Kirchhoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4314-531X","authenticated-orcid":false,"given":"Andreas","family":"Lederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Lorenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gammel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"7786_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"7786_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","volume":"172","author":"KA Roehl","year":"2004","unstructured":"Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004;172:910\u20134. https:\/\/doi.org\/10.1097\/01.ju.0000134888.22332.bb.","journal-title":"J Urol"},{"issue":"5","key":"7786_CR3","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.eururo.2007.01.015","volume":"51","author":"MN Simmons","year":"2007","unstructured":"Simmons MN, Stephenson AJ, Klein EA. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol. 2007;51(5):1175\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2007.01.015.","journal-title":"Eur Urol"},{"key":"7786_CR4","doi-asserted-by":"publisher","unstructured":"Vargas HA, Martin-Malburet AG, Takeda T, Corradi RB, Eastham J, Wibmer A, et al. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng\/ml following prostatectomy: How much information can conventional imaging provide? Urol Oncol. 2016;34:482.e5-.e10. https:\/\/doi.org\/10.1016\/j.urolonc.2016.05.026.","DOI":"10.1016\/j.urolonc.2016.05.026"},{"key":"7786_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027.","journal-title":"Eur Urol"},{"key":"7786_CR6","unstructured":"Network NCC. NCCN clinical practice guidelines in oncology: prostate cancer. Version 4.2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459. Accessed December 7, 2025."},{"key":"7786_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","volume":"5","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5:856\u201363. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0096.","journal-title":"JAMA Oncol"},{"key":"7786_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/ju.0000000000003493","volume":"210","author":"AB Jani","year":"2023","unstructured":"Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, et al. Diagnostic performance and safety of (18)F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Urol. 2023;210:299\u2013311. https:\/\/doi.org\/10.1097\/ju.0000000000003493.","journal-title":"J Urol"},{"key":"7786_CR9","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.Ccr-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674\u201382. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-4573.","journal-title":"Clin Cancer Res"},{"key":"7786_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2024.101532","volume":"9","author":"BH Lowentritt","year":"2024","unstructured":"Lowentritt BH, Jani AB, Helfand BT, Uchio EM, Morris MA, Michalski JM, et al. Impact of clinical factors on (18)F-flotufolastat detection rates in men with recurrent prostate cancer: exploratory analysis of the phase 3 SPOTLIGHT study. Adv Radiat Oncol. 2024;9:101532. https:\/\/doi.org\/10.1016\/j.adro.2024.101532.","journal-title":"Adv Radiat Oncol"},{"key":"7786_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer\u2014updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77:403\u201317. https:\/\/doi.org\/10.1016\/j.eururo.2019.01.049.","journal-title":"Eur Urol"},{"key":"7786_CR12","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1007\/s00259-021-05501-1","volume":"48","author":"JH R\u00fcschoff","year":"2021","unstructured":"R\u00fcschoff JH, Ferraro DA, Muehlematter UJ, Laudicella R, Hermanns T, Rodewald A-K, et al. What\u2019s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns. Eur J Nucl Med Mol Imaging. 2021;48:4042\u201353. https:\/\/doi.org\/10.1007\/s00259-021-05501-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7786_CR13","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2967\/jnumed.124.267591","volume":"65","author":"P Thin","year":"2024","unstructured":"Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J, et al. Clinical factors that influence repeat 68Ga-PSMA-11 PET\/CT scan positivity in patients with recurrent prostate cancer under observation after a negative 68Ga-PSMA-11 PET\/CT scan: a single-center retrospective study. J Nucl Med. 2024;65:1571\u20136. https:\/\/doi.org\/10.2967\/jnumed.124.267591.","journal-title":"J Nucl Med"},{"key":"7786_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-020-00740-z","volume":"10","author":"A Wurzer","year":"2020","unstructured":"Wurzer A, Parzinger M, Konrad M, Beck R, G\u00fcnther T, Felber V, et al. Preclinical comparison of four [(18)F, (nat)Ga]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics. EJNMMI Res. 2020;10:149. https:\/\/doi.org\/10.1186\/s13550-020-00740-z.","journal-title":"EJNMMI Res"},{"key":"7786_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668\u201374. https:\/\/doi.org\/10.2967\/jnumed.115.154153.","journal-title":"J Nucl Med"},{"key":"7786_CR16","unstructured":"Administration UFaD. Highlights of prescribing information: Gallium Ga 68 PSMA-11 Injection. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212642s000lbl.pdf. Accessed December 7, 2025."},{"key":"7786_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/j.eururo.2023.02.002.","journal-title":"Eur Urol"},{"key":"7786_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.semnuclmed.2023.11.001","volume":"54","author":"AF Voter","year":"2024","unstructured":"Voter AF, Werner RA, Savas H, Gafita A, Ross AE, Gorin MA, et al. A practical guide to the pearls and pitfalls of PSMA PET imaging. Semin Nucl Med. 2024;54:119\u201331. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.11.001.","journal-title":"Semin Nucl Med"},{"key":"7786_CR19","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591\u20137. https:\/\/doi.org\/10.1001\/jama.281.17.1591.","journal-title":"JAMA"},{"key":"7786_CR20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/0284186X.2020.1790655","volume":"59","author":"G Mjaess","year":"2020","unstructured":"Mjaess G, Vierasu I, Lacroix S, Aoun F, Goldman S, Roumegu\u00e8re T, et al. Is there a role for repeating PSMA PET\/CT after a negative scan in biochemical recurrent prostate cancer? Acta Oncol. 2020;59:1397\u2013400. https:\/\/doi.org\/10.1080\/0284186X.2020.1790655.","journal-title":"Acta Oncol"},{"key":"7786_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15101224","author":"S Rais-Bahrami","year":"2025","unstructured":"Rais-Bahrami S, Davis P, Chau A, Galgano SJ, Chapin BF, Schuster DM, et al. Detection rates of PSMA-PET radiopharmaceuticals in recurrent prostate cancer: a systematic review. Diagnostics. 2025. https:\/\/doi.org\/10.3390\/diagnostics15101224.","journal-title":"Diagnostics"},{"key":"7786_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2967\/jnumed.120.252114","volume":"62","author":"T Tolvanen","year":"2021","unstructured":"Tolvanen T, Kalliokoski K, Malaspina S, Kuisma A, Lahdenpohja S, Postema EJ, et al. Safety, biodistribution, and radiation dosimetry of (18)F-rhPSMA-7.3 in healthy adult volunteers. J Nucl Med. 2021;62:679\u201384. https:\/\/doi.org\/10.2967\/jnumed.120.252114.","journal-title":"J Nucl Med"},{"key":"7786_CR23","first-page":"P52","volume":"64","author":"P Kuo","year":"2023","unstructured":"Kuo P, Hermsen R, Penny R, Postema E. Post-hoc analysis of the LIGHTHOUSE and SPOTLIGHT studies to assess the impact of urinary activity on interpretation of 18F-rhPSMA-7.3 PET\/CT. J Nucl Med. 2023;64:P52-P.","journal-title":"J Nucl Med"},{"key":"7786_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.119.234922","volume":"61","author":"A Wurzer","year":"2020","unstructured":"Wurzer A, Di Carlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, et al. Radiohybrid ligands: a novel tracer concept exemplified by (18)F- or (68)Ga-labeled rhPSMA inhibitors. J Nucl Med. 2020;61:735\u201342. https:\/\/doi.org\/10.2967\/jnumed.119.234922.","journal-title":"J Nucl Med"},{"key":"7786_CR25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2967\/jnumed.121.263371","volume":"63","author":"A Wurzer","year":"2022","unstructured":"Wurzer A, Kunert JP, Fischer S, Felber V, Beck R, Rose F, et al. Synthesis and preclinical evaluation of (177)Lu-labeled radiohybrid PSMA ligands for endoradiotherapy of prostate cancer. J Nucl Med. 2022;63:1489\u201395. https:\/\/doi.org\/10.2967\/jnumed.121.263371.","journal-title":"J Nucl Med"},{"key":"7786_CR26","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1007\/s00259-016-3424-3","volume":"43","author":"CH Pfob","year":"2016","unstructured":"Pfob CH, Ziegler S, Graner FP, K\u00f6hner M, Schachoff S, Blechert B, et al. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1962\u201370. https:\/\/doi.org\/10.1007\/s00259-016-3424-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7786_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17:565\u201374. https:\/\/doi.org\/10.1007\/s11307-015-0850-8.","journal-title":"Mol Imaging Biol"},{"key":"7786_CR28","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7786_CR29","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1001\/archinternmed.2009.427","volume":"169","author":"R Smith-Bindman","year":"2009","unstructured":"Smith-Bindman R, Lipson J, Marcus R, Kim KP, Mahesh M, Gould R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169:2078\u201386. https:\/\/doi.org\/10.1001\/archinternmed.2009.427.","journal-title":"Arch Intern Med"},{"key":"7786_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.juro.2018.08.050","volume":"201","author":"GL Andriole","year":"2019","unstructured":"Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, et al. The impact of positron emission tomography with 18F-fluciclovine on the treatment of biochemical recurrence of prostate cancer: results from the LOCATE trial. J Urol. 2019;201:322\u201331. https:\/\/doi.org\/10.1016\/j.juro.2018.08.050.","journal-title":"J Urol"},{"key":"7786_CR31","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.juro.2010.04.084","volume":"184","author":"G Giovacchini","year":"2010","unstructured":"Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A, et al. [11C]choline positron emission tomography\/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol. 2010;184:938\u201343. https:\/\/doi.org\/10.1016\/j.juro.2010.04.084.","journal-title":"J Urol"},{"key":"7786_CR32","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2018.01.006","volume":"73","author":"I Rauscher","year":"2018","unstructured":"Rauscher I, D\u00fcwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, et al. Efficacy, predictive factors, and prediction nomograms for (68)Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy. Eur Urol. 2018;73:656\u201361. https:\/\/doi.org\/10.1016\/j.eururo.2018.01.006.","journal-title":"Eur Urol"},{"key":"7786_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jmrs.227","volume":"64","author":"L Emmett","year":"2017","unstructured":"Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64:52\u201360. https:\/\/doi.org\/10.1002\/jmrs.227.","journal-title":"J Med Radiat Sci"},{"key":"7786_CR34","doi-asserted-by":"publisher","unstructured":"Wright GL Jr., Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18\u201328. https:\/\/doi.org\/10.1016\/1078-1439(95)00002-y.","DOI":"10.1016\/1078-1439(95)00002-y"},{"key":"7786_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/rlu.0000000000003444","volume":"46","author":"AD Dreyfuss","year":"2021","unstructured":"Dreyfuss AD, Ahn GS, Barsky AR, Gillman JA, Vapiwala N, Pantel AR. 18F-fluciclovine PET\/CT in therapeutic decision making for prostate cancer: a large single-center practice-based analysis. Clin Nucl Med. 2021;46:187\u201394. https:\/\/doi.org\/10.1097\/rlu.0000000000003444.","journal-title":"Clin Nucl Med"},{"key":"7786_CR36","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/s1470-2045(19)30415-2","volume":"20","author":"J Calais","year":"2019","unstructured":"Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20:1286\u201394. https:\/\/doi.org\/10.1016\/s1470-2045(19)30415-2.","journal-title":"Lancet Oncol"},{"key":"7786_CR37","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.2967\/jnumed.121.263707","volume":"63","author":"M Kroenke","year":"2022","unstructured":"Kroenke M, Schweiger L, Horn T, Haller B, Schwamborn K, Wurzer A, et al. Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2022;63:1809\u201314. https:\/\/doi.org\/10.2967\/jnumed.121.263707.","journal-title":"J Nucl Med"},{"key":"7786_CR38","doi-asserted-by":"publisher","first-page":"968","DOI":"10.2967\/jnumed.120.255661","volume":"62","author":"M Chantadisai","year":"2021","unstructured":"Chantadisai M, Buschner G, Kr\u00f6nke M, Rauscher I, Langbein T, Nekolla SG, et al. Positive predictive value and correct detection rate of (18)F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. J Nucl Med. 2021;62:968\u201374.","journal-title":"J Nucl Med"},{"key":"7786_CR39","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2967\/jnumed.116.173492","volume":"57","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Beer AJ, Graner FP, Haller B, Weirich G, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57:1713\u20139. https:\/\/doi.org\/10.2967\/jnumed.116.173492.","journal-title":"J Nucl Med"},{"key":"7786_CR40","doi-asserted-by":"publisher","unstructured":"Rauscher I, Karimzadeh A, Schiller K, Horn T, D'Alessandria C, Franz C, et al. Detection efficacy of (18)F-rhPSMA-7.3 PET\/CT and impact on patient management in patients with biochemical recurrence of prostate cancer after radical prostatectomy and prior to potential salvage treatment. J Nucl Med. 2021;62:1719\u201326. https:\/\/doi.org\/10.2967\/jnumed.120.260091.","DOI":"10.2967\/jnumed.120.260091"},{"key":"7786_CR41","doi-asserted-by":"publisher","first-page":"702","DOI":"10.2967\/jnumed.119.234609","volume":"61","author":"SW Oh","year":"2020","unstructured":"Oh SW, Wurzer A, Teoh EJ, Oh S, Langbein T, Kr\u00f6nke M, et al. Quantitative and qualitative analyses of biodistribution and PET image quality of a novel radiohybrid PSMA, (18)F-rhPSMA-7, in patients with prostate cancer. J Nucl Med. 2020;61:702\u20139. https:\/\/doi.org\/10.2967\/jnumed.119.234609.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07786-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07786-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07786-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:36:40Z","timestamp":1781635000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07786-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7786"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07786-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was originally published under the subscription model but it is now published under an Open Access license.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All reported investigations were conducted in accordance with the Declaration of Helsinki and with national regulations. This retrospective analysis was approved by the local Ethics Committee (permit 99\/19) and the requirement to obtain informed consent was waived. The administration of\n                      18\n                      F-flotufolastat complied with The German Medicinal Products Act, AMG \u00a713 2b, and the responsible regulatory body (Government of Oberbayern).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement to obtain informed consent was waived for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors confirm that human research participants provided informed consent for publication of the images in Figs.\u00a0\n                      \n                      and\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"IR, WAW, and ME report fees from Blue Earth Diagnostics Ltd (consultant, research funding). Further, ME reports fees from Novartis\/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker), ABX GmbH (speaker), and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review), and Bioclinica (image review) outside the submitted work, and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of\n                      18\n                      F-flotufolastat (POSLUMA). WAW reports fees as a consultant and research funding from ITM, Novartis\/AAA, Nuclidium, Pentixapharm, Ratio Therapeutics, and RayzeBio (outside the submitted work). WAW is an editor in the European Journal of Nuclear Medicine and Molecular Imaging.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}